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Purpose or Objective: Since the beginning of clinical activity 
in 2011, approximately 600 patients has been treated with 
hadrons in CNAO (National Center for Oncological 
Hadrontherapy), among which 42 were sacral chordoma 
undergoing carbon ion radiotherapy (CIRT) with a radical 
intent. The aim of the current study is to analyze the 
feasibility of the insertion of a newly customized spacer prior 
CIRT in sacral chordoma patients, in terms of procedure 
validation and patient tolerance, in selected cases where the 
sacral chordoma is contiguous to the rectum or the bowel 
loops in order to safely escalate the dose to the tumor 
target. 
 
Material and Methods: Since 2014 , 6 consecutive sacral 
chordoma patients (3 males and 3 females) eligible for active 
scanning beam delivery CIRT at CNAO (prescribed dose 70.4 
GyE in 16 fractions), were enrolled for spacer placement at 
IRCCS Policlinico San Matteo – Dept. of General Surgery. For 
each patient silicone spacer was shaped according to 
intraoperative findings from a 10x10 cm silicone sheet with a 
width of 1 mm (Distrex, Padua, Italy). Prior to the surgery 
and clinical use, a variety of measurements was performed to 
evaluate the physical stability of the spacer during and after 
irradiation, as well as its main properties when exposed to 
carbon ion beams. During CIRT, at the end and each 3 months 
afterwards, patients were followed up for acute and late 
CIRT toxicity with clinical visit and high field magnetic 
resonance (MRI). 
 
Results: Three patients underwent laparotomic and 3- 
laparoscopic spacer placement. A representative CIRT plan 
recalculation performed on one of the enrolled patient CT 
performed before spacer insertion showed that during CIRT 
the presence of the spacer keeps digestive tract far away 
from the irradiated area, thus the radiation field is 
unaffected by rectum filling or intestine movement. Patient 
enrolled in the study did not show any gastrointestinal 
toxicity during CIRT or at follow up. Patient imaging during 
follow up did not show anatomic variations.  
 
Conclusion: Silicone spacer placement is a valuable tool for 
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Purpose or Objective: To determine the efficacy and the 
morbidity of the post-operative concurrent 
chemoradiotherapy in patients with advanced localized soft 
tissue sarcomas (STS) of the limbs : results of a retrospective 
analysis. 
 
Material and Methods: From 1991 to 2012, 68 patients with 
primary high grade STS of the limb were treated in our 
institution with an adjuvant concurrent chemoradiotherapy, 
following limb sparing surgery The median age was 47.5 years 
(range, 19 to 74). The most common location was the thigh 
(56%). The resection was complete (R0) and marginal (R1) in 
46 (68%), and 22 (32%), respectively. The median tumor size 
was 6 cm (range, 8 to 20cm), deep in 83% of cases, and grade 
was 2 (FNCLCC) in 28 patients (42%) and 3 in 38 (58%), 2 
missing. Adjuvant radiotherapy was delivered by 
brachytherapy (BRT) plus external radiotherapy (EBRT) in 26 
patients (38%) and by EBRT alone in 42 (62%). The median 
dose of BRT and EBRT were respectively 20Gy (range 12 to 
30Gy) and 60Gy (range, 45 to 70). The median time between 
surgery and EBRT was 48 days (range, 20 to 140). Concurrent 
chemotherapy (CT) was a combination of doxorubicin (60 
mg/m2 total dose (TD) and ifosfamide (7,5 g/m2 TD), with a 
median number of 4 cycles (range, 1-4). 
 
Results: With a median follow-up of 105 months (CI95% 89-
125), the 5-year disease-free survival and overall survival 
rates were 67%(CI95 53.9-77) and 81%(CI95 68-89); 25 
relapses were observed (6 local, 18 distant, and 1 local and 
distant). A severe (grade 3-4) hematologic toxicity was 
observed in 32% of cases, mainly leucopenia; 13 patients 
(20%) experienced a dose reduction of CT. Severe non 
hematologic complications occurred in 15 patients (22%), 
mainly acute cutaneous toxicity (14 patients, 21%). Six 
patients (10%) experienced an EBRT interruption. Severe 
wound complications were very rare (2 absesses), without 
secondary operation for wound care. In univariate analysis, 
median EBRT dose was a prognostic factor for hematologic 
severe complications, the median dose being 64Gy in patients 
with grade 3-4 toxicities vs 56Gy in patients with grade 1-2 
toxicities;p=0.01. Tumor location was a prognostic factor for 
grade 3-4 wound complications and acute dermatitis. Indeed, 
50% of complications were grade 3-4 (5/10) when tumor was 
located in upper limb, vs 17% in inferior limb (10/58); 
(p=0.035). No correlation between age, sexe, tumor size, and 
toxicity was found. 
 
Conclusion: Adjuvant concurrent chemoradiotherapy is 
efficient, feasible and well-tolerated in soft tissue sarcomas 
of the limbs. 
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Purpose or Objective: Kaposi sarcoma (KS) is a vascular 
tumor that can affect the skin and the mucosa of the 
digestive, respiratory and urinary tracts, as well as the 
lynphatic system. It is associated to human herpes virus 8 
(HHV-8). There are three principal variants: Classic KS which 
affects older people (mediterranean and jewish askenazi); 
Endemic KS which mainly affectss african children, is a 
fulminant lymphadenopathic desease, and HIV- associated KS 
which affects homosexual men. Patients with Classic KS have 
skin macules on the legs that enlarge and coalesce into 
plaques and nodules. Radiotherapy is an effective treatment 
for localized lesions. 
 
Material and Methods: We retrospectively analized patients 
with classic KS treated in our department between 2004 and 
2014. Until 2012, all our patients were treated with a 3 Gy 
per fraction, 30 Gy total dose treatment schedule. After this 
date most of our patientes were treated with a 2 Gy per 
fraction, 40 Gy total dose treatment schedule. All patients 
were treated with the same technique: two paralel-opposed 
6 Mv photom fields on both legs submerged into water, in 
order to homogenize the dose on the entire surface, and as a 
bolus effect. We observed that some patients treated with 3 
Gy per fraction schedule, had neuropathic pain in both legs, 
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after the end of the radiation treatment, which required the 
use of high dose-opioid and gabaergic pain relievers, 
chronically. In fact, this was the main factor to consider in 
our study. Local control was analized too. 
 
Results: Eight patients were treated with 3 Gy /fraction, four 
of them suffered neuropathic pain in radiation field that 
required chronic drug treatment. (RR 50%). None of the five 
patients treated with the 2 Gy per fraction technique had 
neuropathic pain in legs. 
 
Conclusion: Our preliminary results indicate that the 2 Gy 
per fraction treatment avoids the onset of neuropathic pain 
after the radiation treatment. Althoug the patient 
recruitment was low, we can afirm that both radiation 
techniques were very useful in the classic KS local control. 
The 2 Gy per fraction treatment was not associated to 
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Purpose or Objective: To evaluate the results of stereotactic 
ablative radiotherapy (SABR) in selected metastatic sarcomas 
patients 
 
Material and Methods: Outcomes of 21 consecutive 
metastatic STS patients (32 consecutive lesions) receiving 
SABR between 2012 and 2015 at our center were 
retrospectively analyzed.  
 
Results: Most patients (85%) had a performance status of 0-1 
and the median age at treatment was 62.4 years. Metastases 
treated were localized in lung (37,5%), brain (37,5%), liver 
(9,5%), soft-tissue (12,5%) and pancreas (3%). The median 
size of the treated lesion was 2.1 cm. The median biologic 
equivalent dose delivered was 120 Gy (range, 52.7-213.8 Gy) 
delivered in a median number of 5 fractions (range, 1-13). 
The majority of patients received systemic agents prior SABR 
(16/21). With a median follow-up of 18 months, the 2 years 
local control rate was 86% (CI 95%: 51-100%; median: not 
reached), with four progressives lesions. Only one patient 
experienced a grade 3 toxicity consisting of an ear bleeding. 
Two years overall survival and progression free survival rates 
were respectively 72% (CI 95%: 47-96%) and 39% (CI 95%: 15-
63%). 
 
Conclusion: SABR in metastatic sarcoma seems to be an 
effective tool in local control that might be used as an 
alternative to other local treatments in highly selected 
patients. 
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Purpose or Objective: MRI characteristics and extent of 
disease in glioma is important for surgical planning. However, 
MRI may not adequately guide biopsy location in non-
enhancing tumors. Furthermore, post-radiation changes are 
difficult to differentiate from progressive tumor. We 
previously demonstrated the PET tracer 3,4-dihydroxy-6-
[18F]fluoro-l-phenylalanine(FDOPA) has a sensitivity for 
gliomas and may improve neurosurgical planning in adults. 
This study evaluates the utility of FDOPA-PET/CT imaging in 
biopsy and resection planning in pediatric patients. 
 
Material and Methods: MR/CT and FDOPA-PET/CT images 
were obtained in 5 patients with primary or recurrent 
malignant gliomas. Regions of interest were defined based on 
areas of MRI contrast enhancement (CE) and FDOPA uptake to 
include both concordant (MRI-CE and high-FDOPA) and 
disconcordant (MRI-non-CE and high-FDOPA, MRI-CE and low 
FDOPA) regions. Ratios of maximum tumor SUV (SUVmax) 
normalized to mean SUV (SUVmean) of normal brain tissue 
(T/N) were determined using the SUVmax from each biopsy 
coordinate and the SUVmean from contralateral normal brain 
tissue.  
 
Results: The FDOPA-PET images guided biopsy site selection 
in four patients. One patient with contrast enhancement in 
an eloquent location near a region of prior radiotherapy did 
not undergo biopsy after FDOPA-PET failed to show increased 
uptake. Average tumor SUVmax was 2.135 (range 2.92-1.27), 
and the T/N average T/N ratio was 1.6 (range 1.92-1.18). 
Biopsies within the region of highest uptake were performed 
in 3 patients and were consistent with Grade III or Grade IV, 
despite lack of contrast enhancement 1 patient. In one 
patient, SUVmax was in an eloquent region of thalamus and 
was deemed an unsafe location for biopsy. Biopsy from an 
adjacent region revealed infiltrating glioma, non-diagnostic 
for grade. Regions of increased FDOPA uptake extended 
beyond those identified with MRI in two patients.  
 
Conclusion: FDOPA-PET imaging appears to have utility in 
guiding biopsy region selection and may assist with 
identifying regions of higher-grade disease in pediatric 
patients with astrocytomas. 
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Purpose or Objective: Respiration-induced organ motion is 
one of the main contributors to intrafractional motion, 
limiting the maximum achievable accuracy in radiation 
therapy (RT). Knowledge on respiration-induced organ motion 
in children during RT is extremely scarce and urgently 
needed for better definitions of abdominal and thoracic 
safety margins. It also allows to assess whether developments 
and introduction of child-friendly breathing exercises and/or 
coaching during the treatment course could have an added 
value to control and minimize respiration-induced organ 
motion. Therefore, the aim of this study is to investigate how 
respiration influences the diaphragmatic motion, as 
indicative of organ motion in the abdomen and thorax, during 
image guided RT (IGRT) in children and to find possible 
relationships with age and height. In addition, we 
investigated trends in the respiration-induced diaphragmatic 
motion during the treatment course. 
 
Material and Methods: This retrospective study consisted of 
15 patients with a mean age of 10.6 years (range 2.2-16.9 
years) and a mean height of 140 cm (range 90–167 cm), 
treated at our institute between 2006 and 2015, for whom for 
setup correction routinely acquired evaluable images of the 
thorax were available. This amounted to a total of 15 
reference CT (refCT) scans and 86 Cone Beam CT (CBCT) 
scans. CBCTs were reconstructed for the inhale and exhale 
respiratory phases and registered to the refCT using Elekta 
XVI software. First, the vertebrae were aligned. 
Subsequently, the diaphragm was manually aligned in cranio-
caudal (CC) direction only. The result yields the mean peak-
to-peak (PP) motion (i.e., magnitude of motion) of the 
diaphragm in the CC direction, derived from registration 
outcomes of the inhale and exhale CBCTs to the refCT. 
